z-logo
Premium
Cyclosporin A monitoring by 2‐h levels: preliminary target levels in stable pediatric kidney transplant recipients
Author(s) -
Pape L,
Lehnhardt A,
Latta K,
Ehrich JHH,
Offner G
Publication year - 2003
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1046/j.1399-0012.2003.00107.x
Subject(s) - medicine , renal function , confidence interval , urology , kidney transplantation , transplantation , kidney , trough level , gastroenterology , tacrolimus
Clinical trials in adults have shown that management of transplanted patients with cyclosporin A (CsA) 2‐h levels (C2) lead to superior outcome compared with monitoring of 12‐h trough levels (C0). In both adults and children, C2 levels enabled a better estimation of the area under the curve concentration than C0 levels. Therefore, it can be suspected that C2 monitoring might also lead to a better outcome in children. Until now C2 target levels for children have not been defined. We measured C2 levels in 101 stable pediatric kidney recipients with a minimum time of 1 yr after transplantation. C2 levels were compared with changes in glomerular filtration rate (GFR) 6 months later. Median C2 levels in children after renal transplantation were 714 ng/mL (95% confidence interval 654–774). Patients with C2 levels below 750 ng/mL had a significantly higher percentage of decline in GFR than patients with C2 levels above 750 ng/mL (p < 0.05). In children with C2 levels below 500 ng/mL three acute rejections occurred in comparison with no rejection in the remaining patients (p < 0.05). We conclude that the lower C2 target level should be above 750 ng/mL in stable pediatric transplant recipients. An upper target level above 1000 ng/mL should be avoided. The question, whether C2 monitoring in pediatric kidney recipients is superior to C0 monitoring, is yet to be answered.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here